Sounds to me like you have more than just high risk money at stake. As many here at the board have advised that is not a good strategy, but to each they own.
You seem to have missed the fact that Anavex has multiple shots on goal. Each of which will make the company. It is true that AD is the biggest indication of the near term possibilities. That is not the only indication that will make the company. AD will be the 20 to 30X. PDD-PD will be the 10X. Rett of Fragile X will be a 5 to 10X. None of the above will be 40 cents.
At this point the available evidence suggests to me that an outright fail on AD is unlikely. A mediocre outcome is possible. Even then the SOC is so low that a mediocre outcome will likely result in an approval even if 2-73 is not the wonderful AD drug that is hoped.
I'm not feeling lucky. I'm feeling well researched.
Market Data 
Markets 
AI
